Business
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
CHICAGO, October 15, 2025--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany.
About this update from Ai, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/093792ccd2c3a973f776fd8910991ab4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/99ZwLkhtXL7AsQqfO.p4Dg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/093792ccd2c3a973f776fd8910991ab4","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/AMQZoHFKBv0mNsSIV.7FOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/093792ccd2c3a973f776fd8910991ab4","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, October 15, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany.","length":338,"tagName":"p"},{"type":"text","content":""We’re sharing research at ESMO Congress 2025, including two oral presentations, that highlight the growing role of real-world data and AI in developing more effective, personalized cancer treatments," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "These findings not only advance the development of new therapies but also equip clinicians with data-driven insights to guide patient care."","length":429,"tagName":"p"},{"type":"text","content":"This year, Tempus will highlight its latest scientific and clinical research findings via two oral presentations and four poster presentations.","length":143,"tagName":"p"},{"type":"text","content":"Oral Presentations:","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker","length":172,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Date/Time: October 17, 2025; 4:35 - 4:40pm CEST","length":47,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Location: Karlsruhe Auditorium - Hall 5.2","...